Lipo-prostaglandin E1 improves renal hypoxia evaluated by BOLD-MRI in patients with diabetic kidney disease
Related Experiment Video
Updated: Feb 11, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Zhi-Cheng Li1, Yu-Zhe Cai2, Zhi-Gang Tang3
1Department of Nephrology, West China Hospital of Sichuan University, Chengdu, Sichuan 610041, China; Department of Nephrology, Zigong First People's Hospital, Zigong, Sichuan 643000, China.
Objective:
To evaluate the effect of lipo-PGE1 on renal hypoxia in patients with DKD by BOLD-MRI.
Materials And Methods:
All patients were divided into DKD group and CKD-without-diabetes group. All patients received intravenous 10 μg lipo-PGE1 once daily for 14 days. BOLD-MRI was performed before and after lipo-PGE1 administration to acquire renal CR2* and MR2* values.
Results:
Renal MR2* value in DKD group after lipo-PGE1 treatment were significantly decreased compared with the baseline. However, no significant differences in MR2* values were found in the CKD-without-diabetes group.
Conclusions:
Lipo-PGE1 was shown to improve kidney medullary oxygenation in patients with DKD.
Related Concept Videos
Kidney Structure
Chronic Kidney Disease I: Introduction
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Chronic Kidney Disease II: Clinical Manifestations
Hypoxia
Types of Hypoxia
There are four primary types of hypoxia, each resulting from a different cause:
1. Anemic hypoxia: This type occurs due to insufficient oxygen delivery caused by a lack of red blood cells (RBCs) or RBCs with abnormal or...
Chronic Kidney Disease III: Interprofessional Care

